GlassScriptPhysician profile
Jay B Madhure
NPI 1770518714
$2,546.94
in general payments reported to CMS, 2019-2025
15 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Adolescent Medicine (Family Medicine) provider received nationally (typical 2025 total: $135).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2021: $353 · 2022: $418 · 2023: $127 · 2024: $141 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $539.49 | 2019-2025 | Wegovy, Saxenda |
| Janssen Pharmaceuticals, INC | $455.98 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $253.58 | 2019 | |
| Sanofi-Aventis U.S. LLC | $249.99 | 2019-2021 | |
| Allergan, INC. | $240.00 | 2019 | |
| Amgen INC. | $141.41 | 2024 | Evenity, Prolia |
| Pfizer INC. | $128.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2019 | |
| Abbvie INC. | $119.53 | 2021 | |
| Redhill Biopharma INC. | $114.21 | 2022 | |
| Merck Sharp & Dohme LLC | $75.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $51.97 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $19.33 | 2025 | Zoryve |
| Irhythm Technologies, INC. | $17.16 | 2023 | Zio Xt Patch |
| Phadia US INC. | $15.35 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Madhure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.